Linked Life Data

11497352

Source:http://linkedlifedata.com/resource/pubmed/id/11497352

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2001-8-10
pubmed:abstractText
Several approaches have been undertaken in the attempt to inhibit hepatitis C virus (HCV) translation. Antisense oligonucleotides (AS ONs) have proven to be invaluable in the characterization of the HCV internal ribosome entry site (IRES). Chemical modification of oligonucleotides has resulted in optimized stability and specificity. Artificial ribozymes have also been developed to target the HCV IRES. Both techniques have demonstrated efficacy in vitro and in vivo. Various studies have identified cellular cofactor proteins that are required for IRES function, which may present themselves as intervention targets. Recent experiments have revealed that the HCV IRES uses a novel mechanism of recruiting translational components. These new advances in understanding the mechanism of HCV translation could lead to the development of novel IRES inhibitor strategies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1464-8431
pubmed:author
pubmed:issnType
Print
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
278-87
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
Hepatitis C IRES: translating translation into a therapeutic target.
pubmed:affiliation
Schering-Plough Research Institute, Department of Antiviral Therapy, Kenilworth, NJ 07033, USA. ronald.jubin@spcorp.com
pubmed:publicationType
Journal Article, Review